Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,505,210
  • Shares Outstanding, K 1,028,111
  • Annual Sales, $ 113,290 K
  • Annual Income, $ -351,400 K
  • EBIT $ -256 M
  • EBITDA $ -241 M
  • 60-Month Beta 0.13
  • Price/Sales 64.80
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 120.61% (+1.52%)
  • Historical Volatility 139.37%
  • IV Percentile 78%
  • IV Rank 43.65%
  • IV High 192.15% on 04/17/25
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 5) 0.92 (12.58%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 18,502
  • Volume Avg (30-Day) 42,643
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 692,756
  • Open Int (30-Day) 742,658
  • Expected Range 6.38 to 8.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.07
  • Low Estimate $-0.09
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.54 +11.62%
on 03/24/26
10.58 -31.00%
on 03/03/26
-3.14 (-30.08%)
since 03/02/26
3-Month
2.03 +259.61%
on 01/05/26
12.43 -41.27%
on 02/25/26
+5.28 (+261.39%)
since 01/02/26
52-Week
1.83 +298.91%
on 05/07/25
12.43 -41.27%
on 02/25/26
+4.25 (+139.34%)
since 04/02/25

Most Recent Stories

More News
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit

SAN DIEGO , April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded...

IBRX : 7.30 (+2.24%)
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired...

IBRX : 7.30 (+2.24%)
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW ORLEANS , April 3, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until May 26, 2026  to file lead plaintiff applications...

IBRX : 7.30 (+2.24%)
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 26, 2026  deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased...

IBRX : 7.30 (+2.24%)
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?

IBRX : 7.30 (+2.24%)
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 3, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio"...

IBRX : 7.30 (+2.24%)
Deadline Approaching: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Law Offices of Howard G. Smith reminds investors of the upcoming  May 26, 2026  deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ImmunityBio,...

IBRX : 7.30 (+2.24%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors...

IBRX : 7.30 (+2.24%)
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm

NEW YORK , April 1, 2026 /PRNewswire/ --

IBRX : 7.30 (+2.24%)
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or...

IBRX : 7.30 (+2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 7.94
2nd Resistance Point 7.65
1st Resistance Point 7.47
Last Price 7.30
1st Support Level 7.00
2nd Support Level 6.71
3rd Support Level 6.53

See More

52-Week High 12.43
Fibonacci 61.8% 8.38
Last Price 7.30
Fibonacci 50% 7.13
Fibonacci 38.2% 5.88
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.